MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) CFO Douglas J. Swirsky sold 6,939 shares of MaxCyte stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $3.18, for a total value of $22,066.02. Following the transaction, the chief financial officer now directly owns 111,811 shares of the company's stock, valued at approximately $355,558.98. The trade was a 5.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
MaxCyte Stock Down 6.1 %
MXCT stock opened at $3.07 on Friday. The business has a fifty day moving average of $4.07 and a 200-day moving average of $3.94. The company has a market cap of $325.51 million, a P/E ratio of -9.03 and a beta of 1.35. MaxCyte, Inc. has a twelve month low of $2.76 and a twelve month high of $5.26.
Analyst Ratings Changes
MXCT has been the subject of a number of recent analyst reports. Stifel Nicolaus dropped their target price on shares of MaxCyte from $11.00 to $9.00 and set a "buy" rating for the company in a research report on Wednesday, March 12th. BTIG Research set a $6.00 target price on shares of MaxCyte and gave the company a "buy" rating in a research note on Wednesday, March 12th.
View Our Latest Report on MXCT
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC raised its stake in shares of MaxCyte by 123.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,564 shares of the company's stock worth $31,000 after buying an additional 4,173 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of MaxCyte during the 3rd quarter valued at $51,000. BNP Paribas Financial Markets acquired a new position in shares of MaxCyte in the 4th quarter valued at $56,000. Prudential Financial Inc. bought a new position in shares of MaxCyte in the 4th quarter worth $65,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in shares of MaxCyte during the fourth quarter worth $74,000. 68.81% of the stock is currently owned by institutional investors and hedge funds.
About MaxCyte
(
Get Free Report)
MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
